The content of this website is intended for United States audiences only.

Report an Adverse Event
/-/media/project/gileadclinicaltrial/header/arrow-right-img.svg
Back Arrow Back to search results
Global Share

STATUS Will Be Recruiting

Study of GS-5319 in Adults With Solid Tumors

LAST UPDATED

August 17 2025

Clinicaltrials.gov ID

NCT07128303

OVERVIEW

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-5319 in Adults With MTAP-deleted Advanced Solid Tumors

PROTOCOL SUMMARY

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).

View More

Participation Requirements

Calendar

Age

18 Years +

Condition

Sex

ALL

Healthy Icon

Healthy Volunteers

No

Study Details

Medical Condition

Advanced Solid Tumor

Gender

N/A

Date

August 2025 - July 2028

Study Type

INTERVENTIONAL

Study Phase

PHASE1

Product

GS-5319

Eligibility Information

Inclusion

Inclusion Criteria

  • Participants diagnosed with histologically or cytologically confirmed solid tumor types who have progressed despite standard therapy, are intolerant to standard therapy, or are ineligible for standard therapy in the advanced setting (locally-advanced or metastatic).
  • Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient. Deoxyribonucleic acid (DNA) sequencing may be assessed locally such as by local next-generation sequencing (NGS) or by central laboratory assay when available.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  • Adequate organ function
  • Age ≥ 18yrs old ( ≥ 19 years old for patients in South Korea)
  • Participants must meet the following tissue requirements:
  • 1. Part A and B: pretreatment tumor tissue is required
VIEW MORE
Exclusion

Exclusion Criteria

  • Active second malignancy. Participants with a history of malignancy who have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with surgically cured tumors with low risk of recurrence may be enrolled.
  • Positive serum pregnancy test or participant who is breastfeeding.
  • Requirement for ongoing therapy with any prohibited medications.
  • Have not recovered (ie, returned to Grade 1 or baseline) from adverse events (AEs) due to a previously administered agent.
  • Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.
  • Ascites or pleural effusion that is symptomatic and/or requiring medical intervention.
  • Active human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.
VIEW MORE